Zheng S, et al. (2020) TRIM6 promotes colorectal cancer cells proliferation and response to thiostrepton by TIS21/FoxM1. J Exp Clin Cancer Res 39, 23 31992359

This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.

Click on the protein name to open the protein page, and on the RSD number to open the site page.

Download

K5-ub - BTG2 (human) ▲

Modsite: ___MSHGkGTDMLPE SwissProt Entrez-Gene Orthologous residues BTG2 (human): K5‑ub, BTG2 (mouse): K5‑ub, BTG2 (rat): K5‑ub Characterization Methods used to characterize site in vivo:  flow cytometry, immunoprecipitation, mass spectrometry, mutation of modification site, western blotting Disease tissue studied:  colorectal cancer, colorectal carcinoma Relevant cell lines - cell types - tissues:  HCT116 (intestinal), HCT8 (intestinal), LoVo (intestinal), SW620 (intestinal) Cellular systems studied:  cell lines Species studied:  human Enzymes shown to modify site in vitro:  Type Enzyme UBIQUITIN LIGASE TRIM6 (human) Upstream Regulation Potential in vivo enzymes for site:  Type Enzyme Evidence Notes UBIQUITIN LIGASE TRIM6 (human) co-immunoprecipitation Downstream Regulation Effect of modification (function):  protein degradation Effect of modification (process):  cell cycle regulation, cell growth, induced